| Title: | Incidence of type 2 diabetes mellitus in men receiving finasteride and tamsulosin: a cross-validation cohort study using data from China and UK populations |
| Journal: | Diabetes Research and Clinical Practice |
| Published: | 6 Aug 2026 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/42562182/ |
| DOI: | https://doi.org/10.1016/j.diabres.2026.113478 |
Publication 21059
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
AIM: To investigate the incidence of T2DM associated with finasteride and tamsulosin use in Chinese and UK populations.</p>
METHODS: Using the Exchange Xiamen PLatform Of Resident E-health Records (EXPLORER) database in China and the UK Biobank (UKB), this study included men aged 40-80 years diagnosed with benign prostatic hyperplasia. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox models, incorporating overlap weighting.</p>
RESULTS: The EXPLORER cohort comprised 34,075 patients, with 21,399 untreated, 2,122 receiving finasteride monotherapy, 5,012 receiving tamsulosin monotherapy, and 5,542 receiving combination therapy. The UKB cohort comprised 11,905 patients, with 7,050 untreated, 492 receiving finasteride monotherapy, 3,105 receiving tamsulosin monotherapy, and 1,258 receiving combination therapy. Compared to patients receiving tamsulosin monotherapy, those receiving finasteride monotherapy showed a higher T2DM risk in the EXPLORER cohort (HR = 1.36 [95% CI: 1.15-1.60]), while no statistically significant association was observed in the UKB cohort (HR = 1.32 [95% CI: 0.96-1.82]). When compared to non-treatment, finasteride monotherapy was not associated with an elevated T2DM risk (EXPLORER: HR = 1.00 [95% CI: 0.89-1.13]; UKB: HR = 1.04 [95% CI: 0.77-1.41]), whereas tamsulosin monotherapy and combination therapy were associated with a reduced T2DM risk (EXPLORER: HR = 0.71 [95% CI: 0.64-0.80] and HR = 0.44 [95% CI: 0.40-0.49], respectively; UKB: HR = 0.67 [95% CI: 0.56-0.81] and HR = 0.45 [95% CI: 0.34-0.59], respectively).</p>
CONCLUSIONS: These findings suggest potential benefits of tamsulosin against T2DM and underscore the need for careful monitoring of T2DM risk in finasteride users.</p>
9 Authors
- Yile You
- Xianglong Meng
- Yuhao Li
- Jieying Chen
- Qing Yuan
- Ming Liu
- Li Wei
- Rongtian Zheng
- Shengfeng Wang
Enabling scientific discoveries that improve human health